Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance.

Autor: Lin H; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Tison K; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA., Du Y; Department of Computational Medicine & Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA., Kirchhoff P; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA., Kim C; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea., Wang W; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Yang H; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea., Pitter M; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Yu J; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Liao P; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Zhou J; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Vatan L; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Grove S; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Wei S; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Vigil T; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA., Shah YM; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA., Mortensen R; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA., Kryczek I; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Garmire L; Department of Computational Medicine & Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA., Sivaccumar JP; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., Ramesh AK; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., Zhang N; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., An Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., Wang S; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Medicinal Chemistry, University of Michigan Medical School, Ann Arbor, MI, USA., Zou W; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA; Graduate Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA. Electronic address: wzou@umich.edu.

Publikováno v: Cancer cell [Cancer Cell] 2024 Dec 09; Vol. 42 (12), pp. 2032-2044.e6. Date of Electronic Publication: 2024 Nov 07.

Exploring barriers to commercial peanut oral immunotherapy treatment during COVID-19.

Autor: Leef C; Children's Healthcare of Atlanta, Atlanta, Ga., Horton C; Children's Healthcare of Atlanta, Atlanta, Ga., Lee T; Children's Healthcare of Atlanta, Atlanta, Ga; Emory University School of Medicine, Atlanta, Ga., Lee G; Children's Healthcare of Atlanta, Atlanta, Ga; Emory University School of Medicine, Atlanta, Ga., Tison K; Emory University School of Medicine, Atlanta, Ga., Vickery BP; Children's Healthcare of Atlanta, Atlanta, Ga; Emory University School of Medicine, Atlanta, Ga. Electronic address: brian.vickery@gmail.com.

Publikováno v: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2022 Jan; Vol. 10 (1), pp. 309-311.e1. Date of Electronic Publication: 2021 Nov 09.

P360 DELIVERING EVIDENCE-BASED ASTHMA EDUCATION IN THE WORLD OF TELEMEDICINE: A QUALITY IMPROVEMENT PROJECT

Autor: Tison, K.

Publikováno v: In Annals of Allergy, Asthma & Immunology November 2020 125(5) Supplement:S43-S44

M312 A CASE FOR ORAL CHALLENGE IN PATIENTS WITH HIGH PEANUT SENSITIVITY TO GUIDE TREATMENT DECISIONS

Autor: Tison, K., Patel, K., Vickery, B.

Publikováno v: In Annals of Allergy, Asthma & Immunology November 2019 123(5) Supplement:S128-S128

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.